A Phase I Dose Escalation Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants

Trial Profile

A Phase I Dose Escalation Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 27 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 11 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top